Ibutilide

Drug Profile

Ibutilide

Alternative Names: Corvert Injection; U 70226E

Latest Information Update: 09 Sep 2003

Price : $50

At a glance

  • Originator Pfizer
  • Class Class III antiarrhythmics; Small molecules; Sulfonamides
  • Mechanism of Action Potassium channel antagonists; Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Atrial fibrillation; Atrial flutter
  • Discontinued Arrhythmias

Most Recent Events

  • 09 Sep 2003 A study has been added to the adverse events and Arrythmias therapeutic trials sections
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 04 Feb 2003 A study has been added to the adverse events and Arrhythmias therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top